Literature DB >> 19629981

Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI.

Deanna L Langer1, Theodorus H van der Kwast, Andrew J Evans, John Trachtenberg, Brian C Wilson, Masoom A Haider.   

Abstract

PURPOSE: To develop a multi-parametric model suitable for prospectively identifying prostate cancer in peripheral zone (PZ) using magnetic resonance imaging (MRI).
MATERIALS AND METHODS: Twenty-five radical prostatectomy patients (median age, 63 years; range, 44-72 years) had T2-weighted, diffusion-weighted imaging (DWI), T2-mapping, and dynamic contrast-enhanced (DCE) MRI at 1.5 Tesla (T) with endorectal coil to yield parameters apparent diffusion coefficient (ADC), T2, volume transfer constant (K(trans)) and extravascular extracellular volume fraction (v(e)). Whole-mount histology was generated from surgical specimens and PZ tumors delineated. Thirty-eight tumor outlines, one per tumor, and pathologically normal PZ regions were transferred to MR images. Receiver operating characteristic (ROC) curves were generated using all identified normal and tumor voxels. Step-wise logistic-regression modeling was performed, testing changes in deviance for significance. Areas under the ROC curves (A(z)) were used to evaluate and compare performance.
RESULTS: The best-performing single-parameter was ADC (mean A(z) [95% confidence interval]: A(z,ADC): 0.689 [0.675, 0.702]; A(z,T2): 0.673 [0.659, 0.687]; A(z,Ktrans): 0.592 [0.578, 0.606]; A(z,ve): 0.543 [0.528, 0.557]). The optimal multi-parametric model, LR-3p, consisted of combining ADC, T2 and K(trans). Mean A(z,LR-3p) was 0.706 [0.692, 0.719], which was significantly higher than A(z,T2), A(z,Ktrans), and A(z,ve) (P < 0.002). A(z,LR-3p) tended to be greater than A(z,ADC), however, this result was not statistically significant (P = 0.090).
CONCLUSION: Using logistic regression, an objective model capable of mapping PZ tumor with reasonable performance can be constructed. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19629981     DOI: 10.1002/jmri.21824

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  96 in total

1.  Prototype Design and Phantom Evaluation of a Device for Co-registered MRI/TRUS Imaging of the Prostate.

Authors:  Andriy Fedorov; Sang-Eun Song; Tina Kapur; Robert Owen; Emily Neubauer Sugar; Paul Nguyen; William M Wells; Clare M Tempany
Journal:  Clin Image Based Proced       Date:  2014

Review 2.  Diffusion weighted imaging in prostate cancer.

Authors:  Cher Heng Tan; Jihong Wang; Vikas Kundra
Journal:  Eur Radiol       Date:  2010-10-09       Impact factor: 5.315

3.  Image registration for targeted MRI-guided transperineal prostate biopsy.

Authors:  Andriy Fedorov; Kemal Tuncali; Fiona M Fennessy; Junichi Tokuda; Nobuhiko Hata; William M Wells; Ron Kikinis; Clare M Tempany
Journal:  J Magn Reson Imaging       Date:  2012-05-29       Impact factor: 4.813

Review 4.  Functional MRI for radiotherapy dose painting.

Authors:  Uulke A van der Heide; Antonetta C Houweling; Greetje Groenendaal; Regina G H Beets-Tan; Philippe Lambin
Journal:  Magn Reson Imaging       Date:  2012-07-06       Impact factor: 2.546

5.  Sequential Registration-Based Segmentation of the Prostate Gland in MR Image Volumes.

Authors:  Farzad Khalvati; Aryan Salmanpour; Shahryar Rahnamayan; Masoom A Haider; H R Tizhoosh
Journal:  J Digit Imaging       Date:  2016-04       Impact factor: 4.056

6.  Prostatic ductal adenocarcinoma: an aggressive tumour variant unrecognized on T2 weighted magnetic resonance imaging (MRI).

Authors:  Nicola Schieda; Niamh Coffey; Previn Gulavita; Omran Al-Dandan; Wael Shabana; Trevor A Flood
Journal:  Eur Radiol       Date:  2014-04-01       Impact factor: 5.315

7.  Electronic Medical Record Context Signatures Improve Diagnostic Classification Using Medical Image Computing.

Authors:  Shikha Chaganti; Louise A Mawn; Hakmook Kang; Josephine Egan; Susan M Resnick; Lori L Beason-Held; Bennett A Landman; Thomas A Lasko
Journal:  IEEE J Biomed Health Inform       Date:  2018-12-28       Impact factor: 5.772

8.  The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel.

Authors:  Berrend G Muller; Jurgen J Fütterer; Rajan T Gupta; Aaron Katz; Alexander Kirkham; John Kurhanewicz; Judd W Moul; Peter A Pinto; Ardeshir R Rastinehad; Cary Robertson; Jean de la Rosette; Rafael Sanchez-Salas; J Stephen Jones; Osamu Ukimura; Sadhna Verma; Hessel Wijkstra; Michael Marberger
Journal:  BJU Int       Date:  2013-11-13       Impact factor: 5.588

Review 9.  Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI.

Authors:  Ryan L Brunsing; Natalie M Schenker-Ahmed; Nathan S White; J Kellogg Parsons; Christopher Kane; Joshua Kuperman; Hauke Bartsch; Andrew Karim Kader; Rebecca Rakow-Penner; Tyler M Seibert; Daniel Margolis; Steven S Raman; Carrie R McDonald; Nikdokht Farid; Santosh Kesari; Donna Hansel; Ahmed Shabaik; Anders M Dale; David S Karow
Journal:  J Magn Reson Imaging       Date:  2016-08-16       Impact factor: 4.813

Review 10.  Focal ablation of prostate cancer: four roles for magnetic resonance imaging guidance.

Authors:  Graham Sommer; Donna Bouley; Harcharan Gill; Bruce Daniel; Kim Butts Pauly; Chris Diederich
Journal:  Can J Urol       Date:  2013-04       Impact factor: 1.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.